Ser704
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Phosphorylation Site Page:
Ser704 - CD44 (human)

Site Information
SGLNGEAsKSQEMVH    SwissProt Entrez-Gene
Predicted information: Scansite
Orthologous residues: CD44 (mouse): S740, CD44 iso2 (mouse): S325, CD44 iso30 (human): S704, CD44 (rat): S465
Blast this site against: NCBI  SwissProt  PDB 

In vivo Characterization
Methods used to characterize site in vivo: [32P] bio-synthetic labeling (13), immunoprecipitation (4), mass spectrometry (1, 5, 6, 7, 8, 10, 11, 12), mutation of modification site (13), phospho-antibody (4), western blotting (4)
Disease tissue studied: leukemia (1), acute myelogenous leukemia (1), prostate cancer (4)
Relevant cell line - cell type - tissue: COS (fibroblast) (13), HeLa (cervical) (5, 6, 7, 8), MKN-45 (gastric) (10, 11), MV4-11 (macrophage) (1), P31/FUJ (myocyte) (1), PC3 (prostate cell) (4), TERT20 ('stem, mesenchymal') (12)


Downstream Regulation
Effects of modification on CD44: intracellular localization (13), molecular association, regulation (4)
Effects of modification on biological processes: cell motility, altered (4)
Inhibit interaction with: MMP9 (human) (4)


References

1

Alcolea MP, et al. (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics 11, 453-66
22547687   Curated Info

2

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

3

Phanstiel DH, et al. (2011) Proteomic and phosphoproteomic comparison of human ES and iPS cells. Nat Methods 8, 821-7
21983960   Curated Info

4

Desai B, Ma T, Zhu J, Chellaiah MA (2009) Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface. J Cell Biochem 108, 272-84
19582779   Curated Info

5

(2009) CST Curation Set: 6246; Year: 2009; SILAC: N; Biosample/Treatment: HeLa(cell line)/UV; Disease: cervical adenocarcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

6

(2009) CST Curation Set: 6247; Year: 2009; SILAC: N; Biosample/Treatment: HeLa(cell line)/UV; Disease: cervical adenocarcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

7

(2009) CST Curation Set: 6241; Year: 2009; SILAC: N; Biosample/Treatment: HeLa(cell line)/nocodazole; Disease: cervical adenocarcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

8

(2009) CST Curation Set: 6240; Year: 2009; SILAC: N; Biosample/Treatment: HeLa(cell line)/nocodazole; Disease: cervical adenocarcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

9

(2008) CST Curation Set: 5535; Year: 2008; SILAC: N; Biosample/Treatment: lung(tissue)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

(2008) CST Curation Set: 5568; Year: 2008; SILAC: N; Biosample/Treatment: MKN-45(cell line)/Su11274; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

11

(2008) CST Curation Set: 5569; Year: 2008; SILAC: N; Biosample/Treatment: MKN-45(cell line)/Su11274; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

12

Thingholm TE, et al. (2008) TiO2-Based Phosphoproteomic Analysis of the Plasma Membrane and the Effects of Phosphatase Inhibitor Treatment. J Proteome Res 7, 3304-3313
18578522   Curated Info

13

Neame SJ, Isacke CM (1992) Phosphorylation of CD44 in vivo requires both Ser323 and Ser325, but does not regulate membrane localization or cytoskeletal interaction in epithelial cells. EMBO J 11, 4733-8
1281449   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.